A surprising no to both multiple myeloma uses puts the ball in the FDA's court.
ApexOnco Front Page
Recent articles
The group has canned its first-generation project, hoping that a follow-on will reach more patients.
The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.
The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.
Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.
Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.
Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.
Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.